Seres Therapeutics (MCRB) Stock Forecast & Price Target

$0.77 +0.04 (+5.49%)

(As of 11/22/2024 ET)

Seres Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 4 Analyst Ratings

Sell
1

Hold
1

Buy
2

Based on 4 Wall Street analysts who have issued ratings for Seres Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 1 has given a sell rating, 1 has given a hold rating, and 2 have given a buy rating for MCRB.

Consensus Price Target

$5.08
561.38% Upside

According to the 4 analysts' twelve-month price targets for Seres Therapeutics, the average price target is $5.08. The highest price target for MCRB is $10.00, while the lowest price target for MCRB is $1.25. The average price target represents a forecasted upside of 561.38% from the current price of $0.77.

Get the Latest News and Ratings for MCRB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Seres Therapeutics and its competitors.

MCRB Analyst Ratings Over Time

Type	Current Forecast 11/25/23 to 11/24/24	1 Month Ago 10/26/23 to 10/25/24	3 Months Ago 8/27/23 to 8/26/24	1 Year Ago 11/25/22 to 11/25/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.08	$5.08	$5.08	$13.67
Forecasted Upside	561.38% Upside	621.14% Upside	480.95% Upside	1,088.41% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

MCRB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MCRB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Seres Therapeutics Stock vs. The Competition

Type	Seres Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.25	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	561.38% Upside	27,073.48% Upside	7.66% Upside
News Sentiment Rating	Negative News See Recent MCRB News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	Canaccord Genuity Group 1 of 5 stars	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00	+1,568.03%
11/13/2024	Chardan Capital 1 of 5 stars	Reiterated Rating	Buy ➝ Buy	$1.25 ➝ $1.25	+111.79%
10/24/2024	JPMorgan Chase & Co. 3 of 5 stars	Downgrade	Neutral ➝ Underweight
6/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
3/8/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$25.00	+362.96%
12/8/2022	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$9.00 ➝ $13.00	+97.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:59 PM ET.

MCRB Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Seres Therapeutics is $5.08, with a high forecast of $10.00 and a low forecast of $1.25.
: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There is currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MCRB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MCRB, but not buy additional shares or sell existing shares.
: According to analysts, Seres Therapeutics's stock has a predicted upside of 561.38% based on their 12-month stock forecasts.
: Over the previous 90 days, Seres Therapeutics's stock had 1 downgrade by analysts.
: Seres Therapeutics has been rated by research analysts at Canaccord Genuity Group, Chardan Capital, and JPMorgan Chase & Co. in the past 90 days.
: Analysts like Seres Therapeutics less than other "medical" companies. The consensus rating for Seres Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MCRB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

This page (NASDAQ:MCRB) was last updated on 11/24/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seres Therapeutics (MCRB) Stock Forecast & Price Target